FY2026 Earnings Estimate for TSE:MBX Issued By Bloom Burton

Posted by James Quigley on Apr 11th, 2025

Microbix Biosystems Inc. (TSE:MBX – Free Report) – Bloom Burton dropped their FY2026 EPS estimates for Microbix Biosystems in a report released on Wednesday, April 9th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.02 per share for the year, down from their prior forecast of $0.04. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share. Bloom Burton also issued estimates for Microbix Biosystems’ FY2027 earnings at $0.05 EPS.

Microbix Biosystems Trading Down 6.7 %

Shares of MBX stock opened at C$0.35 on Friday. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15. The stock has a fifty day simple moving average of C$0.43 and a two-hundred day simple moving average of C$0.39. The firm has a market capitalization of C$46.10 million, a PE ratio of 13.33 and a beta of 0.34. Microbix Biosystems has a 52-week low of C$0.29 and a 52-week high of C$0.55.

Insider Transactions at Microbix Biosystems

In other Microbix Biosystems news, Senior Officer Mark Adrian Luscher sold 70,750 shares of Microbix Biosystems stock in a transaction on Monday, March 3rd. The shares were sold at an average price of C$0.43, for a total value of C$30,295.15. Also, Director Cameron Lionel Groome sold 200,000 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of C$0.43, for a total transaction of C$86,500.00. Insiders sold a total of 476,750 shares of company stock valued at $213,995 over the last 90 days. Company insiders own 14.00% of the company’s stock.

Microbix Biosystems Company Profile

(Get Free Report)

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.